Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPH1AG)

Drug Name
TG100801 Drug Info
Synonyms
867331-82-6; TG 100801; TG100801; UNII-1VZO7A0J9S; TG-100801; 1VZO7A0J9S; 4-Chloro-3-(5-methyl-3-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)benzo[e][1,2,4]triazin-7-yl)phenyl benzoate; 4-Chloro-3-(5-methyl-3-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-amino)benzo[e][1,2,4]triazin-7-yl)phenyl benzoate; C33H30ClN5O3; CHEMBL403989; SCHEMBL12198196; KS-00001CQP; BDBM97971; DTXSID20235791; MolPort-027-835-464; BCP02570; 3641AC; ABP000364; ZINC29136020; AKOS016008711; CS-0785; DB05075; NCGC00378840-01; KB-81090; HY-10186; TG100-801; W-5618
Indication
Disease Entry ICD 11 Status REF
Macular degeneration 9B78.3 Phase 2 [1]
Cross-matching ID
PubChem CID
11973736
CAS Number
CAS 867331-82-6
TTD Drug ID
DMPH1AG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Vascular endothelial growth factor (VEGF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Brolucizumab DMW8QNG Wet age-related macular degeneration 9B78.3Z Approved [3]
Squalamine DM3PS2E Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
PF-06439535 DMVHZDP Non-small-cell lung cancer 2C25.Y Phase 3 [5]
M710 DM1PRT6 Diabetic macular edema 9B71.02 Phase 3 [6]
FKB238 DM6R2XF Non-small-cell lung cancer 2C25.Y Phase 3 [7]
KSI-301 DMM2LTC Diabetic macular edema 9B71.02 Phase 3 [8]
TRS003 DMM1VOH Colorectal cancer 2B91.Z Phase 3 [9]
MYL-1402O DMXN2PP Non-small-cell lung cancer 2C25 Phase 3 [10]
SB15 DMTOS6C Neovascular age-related macular degeneration 9B78.3Z Phase 3 [11]
Dilpacimab DMCATH2 Solid tumour/cancer 2A00-2F9Z Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor (VEGF) TT9HKJA VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT00509548) Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD. U.S. National Institutes of Health.
2 Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.
3 Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
4 Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
5 National Cancer Institute Drug Dictionary (drug id 43234).
6 ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
7 Clinical pipeline report, company report or official report of Fujifilm.
8 Clinical pipeline report, company report or official report of Kodiak Sciences.
9 Prevalence of porcine cysticercosis in Vellore, South India. Trans R Soc Trop Med Hyg. 2013 Jan;107(1):62-4.
10 MYL-1402O: A Bevacizumab Biosimilar. Target Oncol. 2022 Jan;17(1):85-88.
11 Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676.
12 Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.